CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended October 1, 2004.
Key Event: On May 28, 2004, the Company completed the acquisition of the remaining 50% interest in Armkel, LLC, consolidating its results into the financial statements from May 29, 2004. This transaction significantly altered the Company's segment structure and financial profile.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 58.2% in the quarter and 37.3% year-to-date. The primary driver was the consolidation of Armkel sales ($114.8M in Q3; $158.3M YTD) and the Unilever oral care business acquired in late 2003.
• Margin Expansion: Gross margin improved significantly (38.2% vs 30.3% in Q3) due to the higher-margin profile of acquired Armkel and Unilever products, partially offset by a $6.2M inventory step-up charge related to the Armkel acquisition.
• Debt Increase: Total debt more than doubled to $901.8M. This reflects the assumption of Armkel's $225M Senior Subordinated Notes, $136M in bank debt, and new Term Loans ($540M total) used to fund the acquisition.
• Interest Expense: Interest expense rose sharply to $17.8M in Q3 (from $4.8M) and $29.3M YTD (from $14.7M). This includes $4.9M in interest expense related to the settlement of the Carter-Wallace shareholder appraisal suit.
• Equity Earnings: Equity in earnings of affiliates decreased significantly ($1.1M in Q3 vs $5.2M prior year) because the Company now consolidates Armkel rather than accounting for it under the equity method.

Outlook, Risks, and Unusual Items

• Unusual Items:
  • Medpointe Settlement: The Company settled legal actions regarding the Carter-Wallace merger, agreeing to pay $8.1M. $4.9M was recorded as interest expense in Q3, and $3.2M was applied to goodwill.
  • Debt Extinguishment: A $7.995M loss on early extinguishment of debt was recorded in the nine-month period due to the write-off of deferred financing costs upon refinancing.
  • Impairment: A $1.5M plant impairment charge was recorded in Q2 2004.
• Guidance & Outlook: Management expects to significantly increase marketing spending in Q4 to support new product launches (e.g., Arm & Hammer Enamel Care, Trojan Warming Sensations) and acquired oral care brands. The Company plans to invest $30M in Del Laboratories, Inc. in Q4.
• Risks & Contingencies:
  • Regulatory: Potential FDA restrictions on nonoxynol-9 (N-9) in condoms could impact financial results.
  • Commodity Costs: Rising energy and raw material prices are being managed through cost reduction and selective price increases.
  • Legal: Pending litigation with Fleming Companies, Inc. regarding bankruptcy preference payments ($4.2M claim).
• Accounting Changes: New rules (EITF 04-8) regarding contingently convertible debt will have an estimated $0.02 dilutive effect on EPS starting in reporting periods ending after December 15, 2004.

Investor Verification Checklist

• Debt Covenants: Verify compliance with the new Credit Agreement leverage ratio (Total Debt to Adjusted EBITDA). The ratio was 3.14x as of Oct 1, 2004, well below the 4.25x maximum.
• Armkel Integration: Confirm the final purchase price allocation and valuation of Armkel tradenames, which are currently at book value pending appraisal.
• Del Labs Investment: Monitor the closing of the $30M investment in Del Laboratories and the associated option rights for the Orajel brand.
• EPS Dilution: Review the impact of the new EITF 04-8 rule on diluted EPS calculations in the upcoming 2004 annual report.
• Working Capital: Assess the sustainability of the $144M operating cash flow given the significant increase in debt service obligations.